Nedaplatin in neoadjuvant treatment of esophageal squamous cell cancer: a single arm, phase II clinical study

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024628

Enrollment

Unknown

Registered

2019-07-19

Start date

2019-08-01

Completion date

Unknown

Last updated

2019-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal squamous cell cancer

Interventions

Case series:Nedaplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed esophageal squamous cell carcinoma; 2. The clinical stage was locally advanced, which was not suitable for endoscopic stripping or resection, and there was no distant metastasis; 3. PS score 0-1; 4. Aged 18 to 75 years old; 5. Had not received anti-tumor treatment before; 6. Normal function of main organs; 7. Voluntary participation.

Exclusion criteria

Exclusion criteria: 1. Concomitant with other tumors; 2. The presence of autoimmune diseases, or the presence of comorbidities requiring long-term use of hormones; 3. Cachexia; 4. Difficulty in long-term follow-up.

Design outcomes

Primary

Measure	Time frame
Postoperative pathological complete remission rate;	—

Countries

China

Contacts

Public ContactZhenyu Ding

West China Hospital, Sichuan University

dingzy3333@163.com+86 18980601957

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 15, 2026